In T2DM patients, the EMPA‐contained therapeutic regimen versus MET monotherapy significantly ameliorated the rate of liver steatosis, serum levels of ALT, anthropometric indicators, and glycated Hb only after 24 weeks of follow‐up. This evidence concerns the gene GSTM1 and fatty liver disease.